The past decade has seen a dramatic increase in the technology that allows the detection of minute amounts of disease-related analytes in biofluids. This is ...
3hon MSN
Biomarker testing has the potential to improve patient outcomes significantly, but its high cost means it's not accessible to everyone.
As of December 2024, Guardant held $840 million of cash and marketable securities. However, it burned through approximately $390 million in 2022, $345 million in 2023, and $275 million in 2024.
Biomarker testing has the potential to improve patient outcomes significantly, but its high cost means it's not accessible to ...
Kettering, is hoping the third time's the charm on her effort to require private insurers to cover "biomarker" medical testing and thereby improve health outcomes in Ohio and cut down on personal ...
Neurofilament light (NFL) is a powerful and sensitive biomarker for tracking neuronal health and disease progression.
Despite the potential benefits of early detection and increasing treatment options for Alzheimer’s disease and related ...
Despite familiarity with cognitive screening and its benefits, current and emerging screening and testing tools for Alzheimer’s disease and related dementias remain vastly underused, according to ...
Study highlights concerns about premature adoption of preeclampsia screening tests, emphasizing the need for clinical utility ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback